Empasiprubart

Phase 3Biologic

Empasiprubart is one of 31 biologic programs targeting Chronic Inflammatory Demyelinating Polyneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyneuropathyRecruiting

Generalized Myasthenia GravisRecruiting

Multifocal Motor Neuropathy (MMN)Recruiting

DermatomyositisActive, not recruiting

Chronic Inflammatory Demyelinating PolyneuropathyPhase 3

Recruiting

Generalized Myasthenia GravisPhase 2

Recruiting

Multifocal Motor Neuropathy (MMN)Phase 1

Recruiting

DermatomyositisPhase 2

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Dermatomyositis

#DrugCompanyPhaseTrials

Xeljanz

PPrism Pharmaceuticals

Approved

2 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Olumiant

2 4

Jakafi

Incyte

Phase 2

1 5

Interleukin 2

EEssen Biotech

Phase 3

1 6

Empasiprubart

Argenx

Phase 3

1 7

NM8074

NNovelMed Therapeutics

Phase 2

1 8

Emapalumab

SSwedish Orphan Biovitrum

Phase 2

1 9

GLPG3667

GGalapagos NV

Phase 2

1 10

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Recruiting

Myasthenia Gravis

NCT07294170

Phase 2Recruiting

Generalized Myasthenia Gravis

NCT07284420

Q2 2028

Phase 2Recruiting

Generalized Myasthenia Gravis

NCT07673627

Q1 2029

Phase 2Not yet recruiting

Guillain-Barré Syndrome

NCT07821762

Q4 2029

Phase 3Active, not recruiting

Multifocal Motor Neuropathy (MMN)

NCT06742190

Clinical

Trials by Indication[1]

Generalized Myasthenia Gravis2 trials

ISA2 to Master Protocol ARGX-999-2-MG-2000 - an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Recruiting· Argenx logo

Argenx·Phase 2·NCT07673627·40 enrolled

An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Recruiting· Argenx logo

Argenx·Phase 2·NCT07284420·70 enrolled

Chronic Inflammatory Demyelinating Polyneuropathy2 trials

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Recruiting· Argenx logo

Argenx·Phase 3·NCT06920004·218 enrolled

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Recruiting· Argenx logo

Argenx·Phase 3·NCT07091630·160 enrolled

Multifocal Motor Neuropathy (MMN)2 trials

An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

Recruiting· Argenx logo

Argenx·Phase 1·NCT07610564·60 enrolled

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults With Multifocal Motor Neuropathy

Active, not recruiting· Argenx logo

Argenx·Phase 3·NCT06742190·154 enrolled

Dermatomyositis1 trial

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis

Active, not recruiting· Argenx logo

Argenx·Phase 2·NCT06284954·3 enrolled

Guillain-Barré Syndrome1 trial

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Efficacy and Safety of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome

Not yet recruiting· Argenx logo

Argenx·Phase 2·NCT07821762·63 enrolled

1 more indication

Myasthenia Gravis1 trial

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting· Argenx logo

Argenx··NCT07294170·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Empasiprubart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Empasiprubart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Empasiprubart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Argenx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Argenx

Empasiprubart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q1 2029

Q4 2029

Trials by Indication[1]

Generalized Myasthenia Gravis2 trials

Chronic Inflammatory Demyelinating Polyneuropathy2 trials

Multifocal Motor Neuropathy (MMN)2 trials

Dermatomyositis1 trial

Guillain-Barré Syndrome1 trial

Myasthenia Gravis1 trial

References

Drug Info

Quick Facts

Related News